Single-cell sequencing identifies activated odorant receptors directly from native olfactory neurons.
Compounds modulate specific gene expression to inhibit alpha-synuclein mediated cellular toxicity in neuronal cells.
Peptides targeting specific galectin-7 residues block dimer formation, resolving the trade-off between inhibitor efficacy and molecular weight.
An Atlastin 2 inhibitor composition reduces endoplasmic reticulum and mitochondria binding to address cellular dysfunction.
Soluble ActRII polypeptides bypass erythropoietin resistance to raise red blood cell levels without compromising bone density.
GCC2-exosome marker composition detects lung cancer via specific primer or antibody binding.
AR condensate modulators target the intrinsic disorder domain to decrease transcriptional complex levels.
PMVK inhibiting siRNA reduces protein levels to enhance radiation sensitivity, overcoming resistance without damaging normal tissues.
A sol-gel protein chip immobilizes target proteins to enable rapid screening of inhibitors against specific molecular interactions.
Multi-omics platform identifies drug mechanisms of action through integrated transcriptomics, proteomics, and metabolomics analysis.
Triple knockout pro-B cells express autonomously active B-cell receptors to select antibodies that bind tumor epitopes while sparing healthy cells.
Segmented heteromeric and homomeric T1R receptor assays distinguish physiologically relevant interactions to improve prediction accuracy.
Aptamer-functionalized capacitive biosensors detect microorganisms via real-time capacitance changes.
A screening assay identifies MYCBP2 modulators using hydroxy-containing substrates to measure ligase activity.